Metronomic methotrexate + celecoxib versus cisplatin chemotherapy on health-related quality of life changes in patients with metastatic/relapsed or inoperable squamous cell cancer of the head and neck.

Trial Profile

Metronomic methotrexate + celecoxib versus cisplatin chemotherapy on health-related quality of life changes in patients with metastatic/relapsed or inoperable squamous cell cancer of the head and neck.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2014

At a glance

  • Drugs Celecoxib (Primary) ; Cisplatin; Methotrexate
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Aug 2014 New trial record
    • 04 Jun 2014 HRQoL results presented at the 19th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top